Showing 1 - 4 results of 4 for search 'DiNardo, C', query time: 0.04s
Refine Results
-
1
Mechanisms of response and resistance to AML therapies by Stoilova, B, Moore, R, Metzner, M, Zheng, Z, Konopleva, M, DiNardo, C, Vyas, P
Published 2020Journal article -
2
AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies by Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, T, Masarova, L, Takahashi, K, Tippett, G, Garcia, J, Bose, P, Jabbour, E, Ravandi, F, Daver, N, Manero, GG, Vyas, P, Kantarjian, H, Konopleva, M, DiNardo, C
Published 2022Conference item -
3
Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML) by DiNardo, C, Stein, A, Stein, E, Fathi, A, Frankfurt, O, Schuh, A, Doehner, H, Martinelli, G, Patel, P, Raffoux, E, Tan, P, Zeidan, A, De Botton, S, Kantarjian, H, Stone, R, Lam, D, Wang, X, Gong, J, Kapsalis, S, Hickman, D, Zhang, V, Winkler, T, Wu, B, Vyas, P
Published 2019Conference item -
4
A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AM... by Papayannidis, C, DiNardo, C, Montesinos, P, Schuh, A, Vyas, P, Wei, A, Ommen, H, Semochkin, S, Kim, H, Larson, R, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, M, Doronin, V, Dohner, H, Fathi, A, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S
Published 2021Conference item